Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center,Neoplasia

当前位置： X-MOL 学术 › Neoplasia › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center
Neoplasia ( IF 4.8 ) Pub Date : 2023-10-27 , DOI: 10.1016/j.neo.2023.100946
Jens von der Grün , Maiwand Ahmadsei , Isabel Breyer , Christian Britschgi , Daniel Eberli , Thomas Hermanns , Joanna Mangana , Henrik Petrowsky , Egle Ramelyte , Patrick Roth , Gabriel Schär , Isabelle Opitz , Michael Weller , Andreas Wicki , Isabell Witzel , Panagiotis Balermpas , Matthias Guckenberger

Background and purpose

To analyze clinical trial activities and patient recruitment numbers into prospective clinical studies for solid malignancies during the COVID-19 pandemic in a tertiary cancer center.

Materials and methods

Patient recruitment numbers in prospective clinical studies of solid malignancies were retrospectively analyzed for the years 2019 – 2021 at the Comprehensive Cancer Center Zurich (CCCZ). Changes in recruitment numbers were tested for association with organ-specific subunits, as well as organizational and treatment-related trial characteristics. To assess differences between categorical variables, Chi-squared test was used. For uni- and multivariate analysis, Cox proportional hazards were calculated.

Results

In 2019, there were a total of 107 studies (registry trials, clinical phase I-III trials, and translational studies) recruiting 304 patients at the CCCZ. During the COVID-19 pandemic in 2020 and 2021, there were 120 and 125 active trials with a total recruitment of 355 and 666 patients, respectively. No significant differences between the subunits and study characteristics in changes of patient recruitment in clinical phase I-III trials were identified when the year prior to the COVID-19 pandemic (2019) was compared to the first year of the pandemic (2020) and to 2020-2021.

Conclusions

Despite healthcare systems around the world have experienced significant disruption due to the COVID-19 pandemic, data from our tertiary cancer center showed that clinical trial activities were maintained at a high level during the pandemic.

中文翻译：

在三级癌症中心招募患者参加 COVID-19 大流行期间实体恶性肿瘤的临床研究

背景和目的

分析三级癌症中心 COVID-19 大流行期间实体恶性肿瘤前瞻性临床研究的临床试验活动和患者招募数量。

材料和方法

苏黎世综合癌症中心 (CCCZ) 对 2019 年至 2021 年实体恶性肿瘤前瞻性临床研究中的患者招募数量进行了回顾性分析。测试了招募数量的变化与器官特异性亚单位的关联，以及组织和治疗相关的试验特征。为了评估分类变量之间的差异，使用卡方检验。对于单变量和多变量分析，计算了 Cox 比例风险。

结果

2019年，CCCZ共有107项研究（注册试验、临床I-III期试验和转化研究）招募了304名患者。在 2020 年和 2021 年的 COVID-19 大流行期间，有 120 项和 125 项活跃试验，分别招募了 355 名和 666 名患者。将 COVID-19 大流行前一年（2019 年）与大流行第一年（2020 年）和2020-2021。